Riskpilot← Back to searchSign inGet full accessJ E Cellanalys AB
ABActiveOrg 5565331856Auravägen 13 Lgh 1101Other human health activities n.e.c. · NACE 8699Est. 19960 employees
Revenue 2024
—
EBITDA margin
—
-43% vs 2023
Equity ratio
3.4%
Financial strength
Net profit 2024
SEK -323K
-25% vs 2023
| Revenue | — | — |
| EBITDA | SEK -41K | -43% |
| Net profit | SEK -323K | -25% |
| Total assets | SEK 3,9M | -34% |
| Equity | SEK 134K | -95% |
| Employees | 0 | — |
Legal name
J E Cellanalys AB
Org number
5565331856
Legal form
Aktiebolag
NACE code
8699 · Other human health activities n.e.c.
Founded
23 augusti 1996
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska driva institut för medicinsk konsultationsverksamhet och behandling av sjukdomar, äga, förvalta och hyra ut bostads- rätter, förvalta och handla med värdepapper samt bedriva därmed förenlig verksamhet.
Address
Auravägen 13 Lgh 1101
Phone
+468251320
Email
sverker.ericdon@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 17 | 0 | 0 | 0 | — |
| Staff expenses | — | — | — | — | — |
| EBITDA | −78 | −101 | −29 | −29 | −41 |
| Depreciation & amort. | −0 | −0 | — | — | −20 |
| EBIT | −78 | −101 | −29 | −29 | −61 |
| Net financials | 3 721 | 1 280 | −46 | −291 | −339 |
| Profit before tax | 2 731 | 890 | −89 | −258 | −323 |
| Tax | −590 | −266 | −8 | — | — |
| Net profit | 2 141 | 624 | −97 | −258 | −323 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 6 220 | 7 411 | 6 857 | 5 931 | 3 914 |
| Equity | 3 181 | 2 805 | 2 708 | 2 450 | 134 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 1 967 | 3 244 | 2 773 | 2 400 | 3 076 |
| Total debt | 1 967 | 3 244 | 2 773 | 2 400 | 3 076 |
EBITDA margin
-4103900.0%
This company
15.8%
Market median
-25974151% vs market
20202024
Equity ratio
3.4%
This company
38.2%
Market median
-91% vs market
20202024
Return on equity
-240.4%
This company
18.4%
Market median
-1407% vs market
20202024
Net profit margin
-32281000.0%
This company
8.1%
Market median
-398530964% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
28.14×
This company
0.62×
Market median
-4439% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
KE Audit | Audit | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Deputy Board Member | 2021 | |
| Former (2) | ||
| Board of Directors | 2020 – 2020 | |
| Deputy Board Member | 2020 – 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
J E Cellanalys AB 
SE Endoskopi ABBoard members of J E Cellanalys AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kurt Erik Kalmelid | Audit | 0 companies |
| Martin Odd Sverker Ericson | Board of Directors | 0 companies |
| Jan Lars-Erik Ericson | Board of Directors | 0 companies |
| Åsa Birgitta Ericson | Deputy Board Member | 0 companies |
| Siri Linnea Luong Ericson | Deputy Board Member | 0 companies |